Experimental Therapeutics

实验治疗学

基本信息

批准号：
8300274
负责人：
MAX S. WICHA
金额：
$ 54.07万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-01 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8300274
关键词：
Address BIRC4 gene Basic Science Beds Biochemical Biological Assay Biological Markers Calendar Cancer Cell Growth Cancer Center Cancer Center Support Grant Cell Cycle Regulation Cell Proliferation Clinic Clinical Clinical Drug Development Clinical Investigator Clinical Oncology Clinical Research Clinical Trials Clinical Trials Design Collaborations Dendrimers Deubiquitinating Enzyme Development Doctor of Philosophy Drug Delivery Systems Drug Industry Drug Kinetics Enrollment Enzyme Inhibitor Drugs Enzyme Inhibitors Erinaceidae Evolution Faculty Funding Future GTP-Binding Proteins Gene Family Generations Genetic Transcription Genomics Glioma Goals Grant Hair Follicle Neoplasm Human Human Resources IL8 gene Image Imatinib Institutes Interleukin 8A Receptor JAK2 gene Laboratories Lead Link MDM2 gene MEKs Magnetism Malignant Neoplasms Measures Medical Medicine Menin Michigan Molecular Molecular Chaperones Molecular Target Names Nanotechnology Normal tissue morphology Nurses Nursing Research Pathway interactions Patients Pharmaceutical Chemistry Pharmacy facility Phase Phosphoric Monoester Hydrolases Phosphotransferases Program Development Proteasome Inhibitor Proteins Proto-Oncogene Proteins c-akt Publications Recruitment Activity Research Research Personnel Research Support Resistance Scientist Signal Pathway Solid Neoplasm Staging Structure Surrogate Markers Testing The Sun Therapeutic Therapeutic Agents Tissues Toxin Translating Translational Research Translations Tumor Stem Cells Tumor Tissue Universities University of Michigan Comprehensive Cancer Center Validation Work Yang base bcr-abl Fusion Proteins cancer stem cell cancer therapy candidate selection cellular targeting chemotherapeutic agent data management design drug discovery improved inhibitor/antagonist innovation iron oxide leukemia member mutant nanoparticle neoplastic cell notch protein novel novel therapeutics oncology operation patient population phase 1 study phase 2 study pre-clinical preclinical study programs protein protein interaction response rho small molecule structural biology tissue preparation treatment strategy tumor

项目摘要

The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.

实验治疗计划（ETP）的总体目标是建立一个世界一流的学术中心，致力于桥接基本和转化科学，以设计创新和有影响力的癌症疗法。该计划最初名为“分子疗法”计划，成立于2004年12月，汇集了来自15个不同部门的41个调查人员的跨学科小组。自从上次融资周期以来，实验治疗计划的研究基础从7,878,482美元增加到104％，增加到16,042,852美元的年度直接研究总额，并提供总年度直接研究支持，其中3,683,482美元来自NCI。在上一个赠款期间，总共有539个实验性治疗计划成员出版物，其中9.3％是概括性的，有21.1％是程序间截面。由Shaomeng Wang博士领导ETP和Judith Sebolt-Leopold，Ph，d。，ETP强烈关注小分子靶向疗法的理性设计和开发，并作为基础科学与临床计划之间的关键联系。 ETP有四个主要的研究主题： i）鉴定新的治疗剂和方法，这些方法靶向人类癌症失调的关键信号通路， ii）改进使用纳米技术平台来解决肿瘤无法访问的药物输送系统， iii）执行铅优化和临床前生物标志物研究，以指导发展候选者选择和临床试验设计， iv）这些新的癌症药物和方法转化为诊所。